Literature DB >> 9393802

Oligoclonality of serum immunoglobulin G antibody responses to Streptococcus pneumoniae capsular polysaccharide serotypes 6B, 14, and 23F.

A H Lucas1, D M Granoff, R E Mandrell, C C Connolly, A S Shan, D C Powers.   

Abstract

Serum antibodies (Abs) specific for the capsular polysaccharides of Streptococcus pneumoniae provide protection against invasive pneumococcal disease. Previous studies indicate that Abs to pneumococcal polysaccharide (PPS) serotypes 1 and 6B have limited clonal diversity. To determine if restricted diversity was a feature common to other PPS specificities, we examined the light (L)-chain expression and isoelectric heterogeneity of type 6B, 14, and 23F Abs elicited in 15 adults following PPS vaccination. At the population level, both PPS-6B and PPS-14 Abs expressed kappa and lambda chains, although 6B Abs more frequently expressed lambda chains lambda and 14 Abs more frequently expressed kappa chains. In individual sera, Abs were generally skewed towards either kappa or lambda expression. 23F-specific Abs had predominantly kappa chains. Isoelectric focusing analyses showed that sera contained one or at most a few immunoglobulin G Ab spectrotypes to all three respective capsular serotypes, a result indicative of oligoclonality. A sequence analysis of a purified PPS-14-specific Ab having a single spectrotype gave uniform amino-terminal sequences for both the heavy chain (V(H)III subgroup) and the L chain (kappaIII-A27 V region). From these results we conclude that within individual adults, serum Ab responses to PPS serotypes 6B, 14, and 23F derive from a small number of dominant B-cell clones, and consequently variable-region expression is probably individually limited as well. Oligoclonality appears to be a general characteristic of human PPS-specific Ab repertoires, and we suggest that this property could lead to individual differences in Ab fine specificity and/or functional activity against encapsulated pneumococci.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393802      PMCID: PMC175735          DOI: 10.1128/iai.65.12.5103-5109.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b.

Authors:  J Amir; X Liang; D M Granoff
Journal:  Pediatr Res       Date:  1990-04       Impact factor: 3.756

2.  Clonal characterization of the human IgG antibody repertoire to Haemophilus influenzae type b polysaccharide. III. A single VKII gene and one of several JK genes are joined by an invariant arginine to form the most common L chain V region.

Authors:  M G Scott; D L Crimmins; D W McCourt; I Zocher; R Thiebe; H G Zachau; M H Nahm
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

3.  Clonal characterization of the human IgG antibody repertoire to Haemophilus influenzae type b polysaccharide. II. IgG antibodies contain VH genes from a single VH family and VL genes from at least four VL families.

Authors:  M G Scott; J J Tarrand; D L Crimmins; D W McCourt; N R Siegel; C E Smith; M H Nahm
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

4.  Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4.

Authors:  D M Musher; B Johnson; D A Watson
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

5.  Structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 23F (American type 23).

Authors:  J C Richards; M B Perry
Journal:  Biochem Cell Biol       Date:  1988-07       Impact factor: 3.626

6.  Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.

Authors:  M A Shelly; H Jacoby; G J Riley; B T Graves; M Pichichero; J J Treanor
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

7.  Isoelectric focusing of human antibody to the Haemophilus influenzae b capsular polysaccharide: restricted and identical spectrotypes in adults.

Authors:  R A Insel; A Kittelberger; P Anderson
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  Human antibodies to group A streptococcal carbohydrate. Ontogeny, subclass restriction, and clonal diversity.

Authors:  P G Shackelford; S J Nelson; A T Palma; M H Nahm
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

9.  Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. II. Specificity.

Authors:  L J Rubinstein; K E Stein
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

10.  Different VL and VH germ-line genes are used to produce similar combining sites with specificity for alpha(1----6)dextrans.

Authors:  P N Akolkar; S K Sikder; S B Bhattacharya; J Liao; F Gruezo; S L Morrison; E A Kabat
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

View more
  18 in total

1.  Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F.

Authors:  A H Lucas; K D Moulton; V R Tang; D C Reason
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides.

Authors:  W R Usinger; A H Lucas
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F.

Authors:  Jianhui Zhou; Kathleen R Lottenbach; Stephen J Barenkamp; Alexander H Lucas; Donald C Reason
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 4.  Antibody repertoires in infants and adults: effects of T-independent and T-dependent immunizations.

Authors:  E E Adderson
Journal:  Springer Semin Immunopathol       Date:  2001-12

5.  Differential idiotype utilization for the in vivo type 14 capsular polysaccharide-specific Ig responses to intact Streptococcus pneumoniae versus a pneumococcal conjugate vaccine.

Authors:  Jesus Colino; Leah Duke; Swadhinya Arjunaraja; Quanyi Chen; Leyu Liu; Alexander H Lucas; Clifford M Snapper
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

6.  Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.

Authors:  S T Test; J Mitsuyoshi; C C Connolly; A H Lucas
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies.

Authors:  H E Baxendale; D Goldblatt
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

8.  Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease.

Authors:  H E Baxendale; M Johnson; R C M Stephens; J Yuste; N Klein; J S Brown; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2007-11-05       Impact factor: 4.330

9.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B.

Authors:  Jianhui Zhou; Kathleen R Lottenbach; Stephen J Barenkamp; Donald C Reason
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.